EDINBURGH, Scotland--(BUSINESS WIRE)-- DexCom, Inc. (Nasdaq: DXCM), a global leader in real-time continuous glucose monitoring for people with diabetes, today announced a significant advancement in ...
DexCom will likely make significant headway in its addressable market in the next five years. The company should also increase its reach by launching new products and entering new countries. Despite a ...
4don MSN
Forget Ozempic: This high‑flying device maker can thrive no matter which weight loss drug wins
Drugmakers won't be the only ones cashing in on the rising popularity of weight loss medicines.
Abbott Laboratories (NYSE: ABT) and Dexcom (NASDAQ: DXCM) are two leading medical device companies that compete against one ...
DexCom is expected to remain an outperformer in the healthcare sector in 2024, driven by M&A activity and the growth of GLP-1 weight loss drugs. The company's continuous glucose monitoring ("CGM") ...
DexCom shares took a slight tumble after earnings were announced Thursday evening off of strong results. Guidance for the year was upgraded due to growing demand and FDA clearance for the Apple Watch ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results